



Clinical Short Communication

Implication of the *SH3TC2* gene in Charcot-Marie-Tooth disease associated with deafness and/or scoliosis: Illustration with four new pathogenic variants

J. Lerat^{a,b,*}, C. Magdelaine^{b,c}, A. Lunati^{b,c}, H. Dzugan^{b,c}, C. Dejoie^c, M. Rego^c, P. Beze Beyrie^d, E. Bieth^e, P. Calvas^e, P. Cintas^f, A. Delaubrier^g, F. Demurger^h, B. Gilbert-Dussardier^{i,j}, C. Goizet^k, H. Journal^h, F. Laffargue^l, L. Magy^{b,m}, F. Taitheⁿ, A. Toutain^o, J.A. Urtizbera^p, F. Sturtz^{b,c}, A.S. Lia^{b,c}

^a Service Oto-Rhino-Laryngologie, Centre Hospitalier Universitaire de Limoges, Limoges, France

^b EA6309, Université de Limoges, Limoges, France

^c Service de Biochimie et Génétique Moléculaire, Centre Hospitalier Universitaire de Limoges, Limoges, France

^d Centre Hospitalier de Pau, Pédiatrie, France

^e Service de Génétique Médicale, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

^f Service de Neurologie et d'explorations fonctionnelles, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

^g Service de Médecine Physique et Rééducation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France

^h Service de Génétique Médicale, Centre Hospitalier Bretagne Atlantique, Vannes, France

ⁱ Service de Génétique Médicale, Centre Hospitalier Universitaire de Poitiers, Poitiers, France

^j EA3808, Université de Poitiers, Poitiers, France

^k Service de Neurogénétique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

^l Service de Génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Limoges, France

^m Service de Neurologie, Centre Hospitalier Universitaire de Limoges, Limoges, France

ⁿ Service de Neurologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Limoges, France

^o Service de Génétique, Centre Hospitalier Universitaire de Tours, Tours, France

^p Centre de Compétence Neuromusculaire, APHP, Filnemus, Centre Hospitalier Hendaye, France

ARTICLE INFO

Keywords:

Charcot-Marie-Tooth
Neuropathy
Hearing loss
Scoliosis
SH3TC2
NGS

ABSTRACT

The autosomal recessive demyelinating form of Charcot-Marie-Tooth can be due to *SH3TC2* gene pathogenic variants (CMT4C, AR-CMTde-*SH3TC2*). We report on a series of 13 patients with AR-CMTde-*SH3TC2* among a French cohort of 350 patients suffering from all type of inheritance peripheral neuropathy. The *SH3TC2* gene appeared to be the most frequently mutated gene for demyelinating neuropathy in this series by NGS. Four new pathogenic variants have been identified: two nonsense variants (p.(Tyr970*), p.(Trp1199*)) and two missense variants (p.(Leu1126Pro), p.(Ala1206Asp)). The recurrent variant p.Arg954* was present in 62%, and seems to be a founder mutation. The phenotype is fairly homogeneous, as all these patients, except the youngest ones, presented scoliosis and/or hearing loss.

1. Introduction

Charcot-Marie-Tooth disease (CMT) is the most frequent inherited peripheral neuropathies (1/2500). So far, variants in > 90 genes have been identified causing either the demyelinating or the axonal form. Duplication of the *PMP22* gene is the most frequent cause of the autosomal dominant demyelinating form. The autosomal recessive demyelinating form is foremost due to *SH3TC2* gene pathogenic variants (CMT4C, or AR-CMTde-*SH3TC2*) [1]. Patients with AR-CMTde-*SH3TC2*

suffer from early severe neuropathy starting in the first decade. Scoliosis and cranial nerve involvement, including hearing loss (HL), are frequently observed [2–4].

We report on a series of 13 patients with AR-CMTde-*SH3TC2* among a French cohort of 350 patients suffering from all type of inheritance peripheral neuropathy. Phenotype-genotype correlations of these specific features have been looked for.

* Corresponding author at: ORL, Hôpital Mère-Enfant, 8 avenue Dominique Larrey, 87042 Limoges, Cedex, France

E-mail address: justine.lerat@chu-limoges.fr (J. Lerat).

<https://doi.org/10.1016/j.jns.2019.06.027>

Received 23 January 2019; Received in revised form 7 June 2019; Accepted 24 June 2019

Available online 26 June 2019

0022-510X/ © 2019 Elsevier B.V. All rights reserved.

Table 1
Phenotypes of our 13 patients presenting with a demyelinating hereditary neuropathy among a cohort of 350 French patients.

Patient		Polyneuropathy										Hearing loss		Scoliosis		Cranial nerve involvement	Other symptoms
Reference Family	Patient (gender/age in years)	Neuropathy	Median nerve motor velocity (m/s)	Age at onset (years)	Sensory nerve impairment	Mild or severe weakness	Proximal muscle involvement	Pes Cavus	Loss of ambulation/sensory ataxia	Present	Degree of severity	Age at onset (age in years)	Present	Degree of severity	Cranial nerve involvement	Other symptoms	
Patient I	F, 22	Sensori-motor demyelinating	28	3	Y	Moderate	N	Y	N/Y	Y	Moderate	16	Y	NC	NC	Sphincter disorders	
Patient II	M, 24	Sensori-motor demyelinating	30	< 8	Y	Moderate	N	Y	N/N	N	/	/	Y	24°	N	/	
Patient III	M, 43	Sensori-motor demyelinating	35	8	Y	Moderate	N	Y	N/Y	Y	NC	NC	Y	Severe	N	/	
Patient IV	F, 23	Sensori-motor demyelinating	25	1	Y	Moderate	N	Y	N/Y	N	/	/	Y	Mild	NC	/	
Patient V	F, 47	Sensori-motor demyelinating	25	4	Y	Severe	N	Y	N/Y	Y	Severe	NC	N	/	Latency of Visual brainstem responses	/	
Patient VI	F, 29	Sensori-motor demyelinating	25	6	NC	Severe	N	N	N/Y	NC	NC	NC	Y	NC	NC	/	
Patient VII	M, 56	Sensori-motor demyelinating	32	Child hood	Y	Moderate	N	Y	N/Y	Y	Moderate progressive	25	Y	NC	N	/	
Patient VIII	F, 68	Sensori-motor demyelinating	34	9	NC	Severe	NC	Y	NC/NC	Y	Moderate slope curve	NC	Y	NC	NC	/	
Patient IX	F, 12	Sensori-motor demyelinating	34	3	Y	Severe	Y	Y	Y/Y	Y	Mild	11	N	/	N	/	
Patient X	M, 9	Sensori-motor demyelinating	30	< 5	N	Moderate	N	Y	Y/Y	N	/	/	Y	Mild < 10°	N	Autism	
Patient XI	F, 71	Sensori-motor demyelinating	30	Teens	Y	Severe	N	Y	N/Y	Y	Severe progressive	< 10	Y	NC	N	Bilateral cataract	
Patient XII	M, 83	Sensori-motor demyelinating	31	73	Y	Severe	N	N	NC/NC	Y	Moderate U-shaped curve	NC	Y	NC	NC	/	
Patient XIII	M, 27	Sensori-motor demyelinating	30	8	Y	Moderate	N	Y	N/N	N	/	/	N	/	N	Muscular pain	

F: Female; M: Male; NC: Not Communicated; /: not applicable; Y: Yes; N: No.

2. Materials and methods

After giving their informed consent, 350 French patients suffering from inherited peripheral neuropathy were screened by *PMP22* multiplex-ligation-dependent-probe-amplification, followed by targeted next-generation-sequencing using a 92-gene custom panel designed for the diagnosis of CMT and associated neuropathies (detailed in [5]; *Supplementary data*).

Patients were selected from diagnostic registries of a French genetic reference center. Previously, a clinical questionnaire has been fulfilled. Patients' ascertainment could be precised thanks to medical records.

The NGS panel included the 44 known CMT genes, 27 genes involved in HSN (Hereditary Sensitive Neuropathy) and HMN (Hereditary Motor Neuropathy) and 21 other genes of interest involved in neuropathies of differential diagnosis. The amplified library was prepared with Ion P1 HiQ Template OT2 200 kit (Ampliseq Custom (Life technologies)), sequenced on Proton sequencer (Life technologies), and mapped to the human reference sequence hg19/GHCh37. Variants were evaluated with Alamut Mutation Interpretation Software (Interactive Biosoftware, Rouen, France) using the NM_024577.3 reference sequence for the *SH3TC2* gene. Databases such as ExAC Genome browser (<http://exac.broadinstitute.org>), dbSNP135 (National Center for Biotechnology Information [NCBI], Bethesda, Maryland, USA, <http://www.ncbi.nlm.nih.gov/projects/SNP/>), Clin Var (www.ncbi.nlm.nih.gov/clinvar), HGMD professional (www.hgmd.cf.ac.uk) and Mutalyzer (<https://mutalyzer.nl/>) were also screened. Pathogenic variants of interest were verified by Sanger sequencing using forward and reverse primer pairs.

For HL screening, MLPA and Sanger sequencing for *GJB2* and *GJB6* were performed.

Table 2

Genotypes of our 13 patients presenting with a demyelinating hereditary neuropathy due to *SH3TC2* among a cohort of 350 French patients. Strong grey color corresponds to nonsense variants, middle grey color to nonsense variant associated to missense variant, mild grey color to missense variants. (F: Female; M: Male; in Red: novel variants found).

Patient			Genotype				
Reference Family	Patient (gender/age in years)	Country	Mutation type	Zygosity	Nucleotide change	Amino acid change	Localization
Patient I	F, 22	France	Nonsense	Homozygous	c.2860C>T	p.Arg954*	Exon11
Patient II	F, 29	France	Nonsense	Homozygous	c.2860C>T	p.Arg954*	Exon11
Patient III	M, 43	France	Nonsense	Homozygous	c.2860C>T	p.Arg954*	Exon11
Patient IV	F, 23	France	Nonsense + Nonsense	Compound heterozygous	c.2860C>T + c.3325C>T	p.Arg954* + p.Arg1109*	Exon11 + Exon14
Patient V	F, 47	France	Nonsense	Homozygous	c.3325C>T	p.Arg1109*	Exon14
Patient VI	F, 29	France	Nonsense + Nonsense	Compound heterozygous	c.2860C>T + c.2910C>A	p.Arg954* + p.Tyr970*	Exon11 + Exon12
Patient VII	M, 56	France	Nonsense	Homozygous	c.3321C>A	p.Tyr1107*	Exon14
Patient VIII	F, 68	France	Nonsense + Missense	Compound heterozygous	c.2860C>T + c.3377T>C	p.Arg954* + p.Leu1126Pro	Exon11 + Exon 15
Patient IX	F, 12	France	Nonsense + Missense	Compound heterozygous	c.2860C>T + c.3511C>T	p.Arg954* + p.Arg1171Cys	Exon11 + Exon 16
Patient X	M, 9	France	Nonsense + Missense	Compound heterozygous	c.2860C>T + c.3511C>T	p.Arg954* + p.Arg1171Cys	Exon11 + Exon 16
Patient XI	F, 71	France	Missense + Nonsense	Compound heterozygous	c.2642A>G + c.3596G>A	p.Asn881Ser + p.Trp1199*	Exon11 + Exon16
Patient XII	M, 83	France	Missense	Homozygous	c.3617C>A	p.Ala1206Asp	Exon16
Patient XIII	M, 27	France	Missense + Missense	Compound heterozygous	c.1969G>A + c.2642A>G	p.Glu657Lys + p.Asn881Ser	Exon11 + Exon11

3. Results and discussion

Diagnosis was positive for 201 patients (57%). As expected, the most frequent pathogenic variant was *PMP22* duplication detected in 52 patients (15%). Deletion of *PMP22* was observed in 29 patients (8%) and pathogenic point variant were detected in 120 patients (34%).

Among these 120 patients diagnosed with point variants, 40 patients presented with a demyelinating neuropathy and the *SH3TC2* gene appeared to be the most frequently mutated with 13 diagnosed patients (32.5%). Details of their phenotypes and genotypes are presented in *Tables 1 and 2*.

3.1. Phenotype

Although some clinical information is missing, we can see that all these patients, except for the youngest patients in our series, presented with scoliosis ($n = 10$; 77%) and/or deafness ($n = 8$; 62%). The phenotype is fairly homogeneous with sensori-motor demyelinating polyneuropathy with early onset before the age of 10, except for one patient with adulthood onset (patient XII).

Sensory ataxia with poor imbalance seems to be a prominent feature, as it was found in nine patients (70%), like Gooding et al. [6].

Cranial nerve involvement is another key point of CMT4C, as it is shown in our study with eight patients reporting HL and one patient with increased latencies of visual brainstem responses. Recently, Kontogeorgiou et al. reported cranial nerve involvement in 31% of the cases [7], and Yger et al. in a French cohort in 71% [4]. HL is the foremost observed condition [8].

Pes cavus was found in eleven cases (85%). Foot deformities are very frequently described in this phenotype [9,10].

Only one patient had a proximal muscle involvement, whereas it has been reported in recent studies [11,12].

3.2. Genotype

In addition to already known pathogenic variants, four new pathogenic variants have been identified: two nonsense variants (c.2910C > A, p.(Tyr970*) and c.3596G > A, p.(Trp1199*)) and two missense variants (c.3377T > C, p.(Leu1126Pro) and c.3617C > A, p.(Ala1206Asp)).

Analysis at the DFNB1 locus did not reveal any pathogenic variant for all diagnosed and known deaf patients, which is in favour of the implication of the *SH3TC2* gene in hearing loss.

The recurrent variant p.Arg954* was present in 62% of our patients. This is similar to another French study by Yger et al. (62.5%) and a Czech study by Lassuthova et al. with 63.2% [4,10].

Thus, this pathogenic variant is prevalent in 5% in Northern Europe, such as Norway [13], and is also frequent in Italy [8,14]. As it is also identified in North America, p.Arg954* seems to be a founder mutation [15,16]. Haplotype analysis should be performed to confirm this hypothesis.

4. Conclusion

SH3TC2 appears to be the most frequently implicated gene in autosomal recessive demyelinating form of CMT in the French population, often associated with scoliosis and/or HL. Sensory ataxia and pes cavus are prominent features of CMT4C. Moreover, p.Arg954* appears to be a founder mutation.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jns.2019.06.027>.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Acknowledgements

We are thankful to the nucleic acid platform BISCHEM, University of Limoges, France. We also thank Sylvie Gautier for English revision.

Declaration of Competing Interests

None.

References

- [1] S. Mathis, C. Goizet, M. Tazir, C. Magdelaine, A.-S. Lia, L. Magy, J.M. Vallat, Charcot-Marie-Tooth diseases: an update and some new proposals for the classification, *J. Med. Genet.* 52 (10) (2015) 681–690.
- [2] J. Senderek, C. Bergmann, C. Stendel, J. Kirfel, N. Verpoorten, P. De Jonghe, V. Timmerman, R. Chrast, M.H. Verheijen, G. Lemke, E. Battaloglu, Y. Parman, S. Erdem, E. Tan, H. Topaloglu, A. Hahn, W. Müller-Felber, N. Rizzuto, G.M. Fabrizi, M. Stuhmann, S. Rudnik-Schöneborn, S. Züchner, J. Michael Schröder, E. Buchheim, V. Straub, J. Klepper, K. Huehne, B. Rautenstrauss, R. Böttner, E. Nelis, K. Zerres, Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy, *Am. J. Hum. Genet.* 73 (5) (2003) 1106–1119.
- [3] H. Azzedine, E. LeGuern, M.A. Salihi, Charcot-Marie-Tooth neuropathy type 4C, in: M.P. Adam, H.H. Ardinger, R.A. Pagon, S.E. Wallace, L.J. Bean, K. Stephens, et al. (Eds.), *GeneReviews*, 2008, pp. 1993–2018 <http://www.ncbi.nlm.nih.gov/books/NBK1340/>.
- [4] M. Yger, T. Stojkovic, S. Tardieu, T. Maisonobe, A. Brice, A. Echaniz-Laguna, Y. Alembik, S. Girard, C. Cazeneuve, E. Leguern, O. Dubourg, Characteristics of clinical and electrophysiological pattern of Charcot-Marie-Tooth 4C, *J. Peripher. Nerv. Syst.* 17 (1) (2012) 112–122.
- [5] J. Lerat, P. Cintas, H. Beauvais-Dzagan, C. Magdelaine, F. Sturtz, A.S. Lia, A complex homozygous mutation in *ABHD12* responsible for PHARC syndrome discovered with NGS and review of the literature, *J. Peripher. Nerv. Syst.* 22 (2) (2017) 77–84.
- [6] R. Gooding, J. Colomer, R. King, D. Angelicheva, L. Marns, Y. Parman, D. Chandler, J. Bertranpetit, L. Kalaydjieva, A novel Gypsy founder mutation, p.Arg1109X in the *CMT4C* gene, causes variable peripheral neuropathy phenotypes, *J. Med. Genet.* 42 (12) (2005) e69.
- [7] Z. Kontogeorgiou, K. Nikolaou, C. Kartanou, M. Breza, M. Panas, G. Karadima, G. Koutsis, Mutational screening of the *SH3TC2* gene in Greek patients with suspected demyelinating recessive Charcot-Marie-Tooth disease reveals a varied and unusual phenotypic spectrum, *J. Peripher. Nerv. Syst.* 24 (1) (2019) 125–130, <https://doi.org/10.1111/jns.12305> (Epub 2019 Feb 6).
- [8] G. Piscoquito, P. Saveri, S. Magri, C. Ciano, C. Gandioli, M. Morbin, D.D. Bella, I. Moroni, F. Taroni, Pareyson D (2016) screening for *SH3TC2* gene mutations in a series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4), *J. Peripher. Nerv. Syst.* 21 (3) (2016 Sep) 142–149, <https://doi.org/10.1111/jns.12175>.
- [9] J. Baets, T. Deconinck, E. De Vriendt, M. Zimoň, L. Yperzeele, K. Van Hoornebeeck, K. Peeters, R. Spiegel, Y. Parman, B. Ceulemans, P. Van Bogaert, A. Pou-Serradell, G. Bernert, A. Dinopoulos, M. Auer-Grumbach, S.L. Sallinen, G.M. Fabrizi, F. Pauly, P. Van den Bergh, B. Bilir, E. Battaloglu, R.E. Madrid, D. Kabzińska, A. Kochanski, H. Topaloglu, G. Miller, A. Jordanova, V. Timmerman, P. De Jonghe, Genetic spectrum of hereditary neuropathies with onset in the first year of life, *Brain* 134 (Pt 9) (2011) 2664–2676, <https://doi.org/10.1093/brain/awr184> (Epub 2011 Aug 11).
- [10] P. Laššuthová, R. Mazanec, P. Vondráček, D. Šišková, J. Haberlová, J. Sabová, P. Seeman, High frequency of *SH3TC2* mutations in Czech HMSN I patients, *Clin. Genet.* 80 (4) (2011) 334–345, <https://doi.org/10.1111/j.1399-0004.2011.01640.x> (Epub 2011 Mar 1).
- [11] K.A. Arntzen, H. Høyer, K. Ørstavik, C. Tallaksen, C. Vedeler, R. Østern, M. Nebuchennikh, G.J. Braathen, T. Fagerheim, Charcot-Marie-Tooth disease type 4C in Norway: clinical characteristics, mutation spectrum and minimum prevalence, *Neuromuscul. Disord.* 28 (8) (2018) 639–645, <https://doi.org/10.1016/j.nmd.2018.06.004> (Epub 2018 Jun 15).
- [12] C.M. de Oliveira, H. Fussiger, P.B. Winckler, J.A.M. Saute, Dropped head syndrome as a manifestation of Charcot-Marie-Tooth disease type 4C, *Neuromuscul. Disord.* 29 (2) (2019) 138–141, <https://doi.org/10.1016/j.nmd.2018.11.010> (Epub 2018 Nov 29).
- [13] H. Høyer, G.J. Braathen, Ø.L. Busk, Ø.L. Holla, M. Svendsen, H.T. Hilmarsen, L. Strand, C.F. Skjelbred, M.B. Russell, Genetic diagnosis of Charcot-Marie-Tooth disease in a population by next-generation sequencing, *Biomed. Res. Int.* 2014 (2014) 210401, <https://doi.org/10.1155/2014/210401> (Epub 2014 Jun 16).
- [14] F. Manganelli, S. Tozza, C. Pisciotto, E. Bellone, R. Iodice, M. Nolano, A. Geroldi, S. Capponi, P. Mandich, L. Santoro, Charcot-Marie-Tooth disease: frequency of genetic subtypes in a southern Italy population, *J. Peripher. Nerv. Syst.* 19 (4) (2014) 292–298, <https://doi.org/10.1111/jns.12092>.
- [15] J.R. Lupski, C. Gonzaga-Jauregui, Y. Yang, M.N. Bainbridge, S. Jhangiani, C.J. Buhay, C.L. Kovar, M. Wang, A.C. Hawes, J.G. Reid, C. Eng, D.M. Muzny, R.A. Gibbs, Exome sequencing resolves apparent incidental findings and reveals further complexity of *SH3TC2* variant alleles causing Charcot-Marie-Tooth neuropathy, *Genome Med.* 5 (6) (2013) 57, <https://doi.org/10.1186/gm461> (eCollection 2013).
- [16] T.L. Varley, P.R. Bourque, S.K. Baker, Phenotypic variability of CMT4C in a French-Canadian kindred, *Muscle Nerve* 52 (3) (2015) 444–449, <https://doi.org/10.1002/mus.24640> (Epub 2015 May 14).